South African pharmacy group Dis-Chem announced in a Sens on Friday that its headline earnings per share declined by 1.6% for the year ended 29 February 2024.
From 1 March 2023 to 29 February 2024, Dis-Chem Pharmacies recorded group revenue growth of 11.1%, to R36.3 billion, as trading conditions continued to strengthen in line with the first-half statement. The results were also boosted by Covid-19 vaccine administration and testing services, which have ended and did not contribute to the current financial period.
“The group is pleased with its performance, driven by a strong second half where earnings before tax increased by 22.0%. As stated at the half year, the group was impacted by the base effects of the prior year’s performance, which were distinctly different across the two halves of the year,” Dis-Chem CEO Rui Morais noted.